Zylox Medical Device Co., a leading innovator in the medical technology sector, is headquartered in China (CN) and operates extensively across Asia and Europe. Founded in 2010, the company has rapidly established itself as a key player in the development of advanced medical devices, particularly in the fields of minimally invasive surgery and diagnostic imaging. Zylox is renowned for its cutting-edge products, including state-of-the-art endoscopic systems and precision surgical instruments, which are designed to enhance patient outcomes and streamline surgical procedures. The company’s commitment to quality and innovation has earned it numerous accolades, solidifying its position as a trusted name in the medical device industry. With a focus on research and development, Zylox continues to push the boundaries of technology, ensuring it remains at the forefront of medical advancements.
How does Zylox Medical Device Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zylox Medical Device Co's score of 24 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Zylox Medical Device Co, headquartered in CN, reported total carbon emissions of approximately 3,069,870 kg CO2e. This figure includes 137,290 kg CO2e from Scope 1 emissions and 2,932,580 kg CO2e from Scope 2 emissions. The company has shown a significant reduction in emissions from the previous year, 2021, when total emissions were about 1,405,140 kg CO2e, comprising 20,840 kg CO2e from Scope 1 and 1,384,300 kg CO2e from Scope 2. Zylox has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or climate pledges. The absence of such commitments may reflect a broader industry context where many companies are still developing comprehensive climate strategies. Overall, Zylox Medical Device Co's emissions data indicates a proactive approach to monitoring and reporting carbon emissions, although further commitments to reduction targets would enhance their climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | |
---|---|---|
Scope 1 | 20,840 | 000,000 |
Scope 2 | 1,384,300 | 0,000,000 |
Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zylox Medical Device Co is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.